Warning for AcelRx on Dsuvia marketing practices

17 February 2021

The US regulator has issued a warning to AcelRx Pharmaceuticals (Nasdaq: ACRX) over its marketing of opioid analgesic Dsuvia (sufentanil), causing shares in the company to fall 8%.

The sublingual tablet, which is approved for the management of acute pain in adults, is used when people are not able to receive treatment orally or through intravenous injection.

The US Food and Drug Administration said that AcelRx had “disseminated promotional communications that undermine key prescribing conditions required for the safe use” of the product.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK